Henlius Achieves Steady Growth in 2025
Henlius has announced impressive financial results for the first half of 2025. The company's revenue reached approximately RMB2.8195 billion, showing a year-on-year increase of 2.7%. With a gross profit of RMB2.1992 billion, up 10.5% YoY, Henlius also reported a net profit of RMB390.1 million. Operating cash flow exhibited remarkable growth, reaching RMB770.9 million, an astonishing 206.8% increase YoY. These statistics reflect the company's robust business model and strategic initiatives.
Surge in Overseas Product Profits
One of the standout aspects of Henlius' performance is the significant growth in profits from overseas product sales, which soared over 200%. The company attributed this success to its strategic focus on international markets and innovative product offerings, creating tremendous opportunities for expansion. Cash inflows from business development agreements reached RMB1 billion, a staggering increase of 280% YoY, highlighting the strong business development efforts Henlius has made.
Commitment to Innovation and Globalization
Henlius is unwavering in its commitment to innovation, having invested RMB995.4 million in research and development during this period, which is a 21.3% increase in R&D expenditures YoY. The company's focus lies in the preclinical development of innovative molecules and establishment of core innovation platforms, ensuring that it stays at the forefront of medical advancements.
Global Reach and Patient Impact
Currently, Henlius has launched 6 products in various international markets, with 4 approved for marketing outside its home country. The company's efforts have benefited over 850,000 patients across approximately 60 markets, including regions in Asia, Europe, Latin America, and North America. This widespread impact demonstrates Henlius' dedication to enhancing patient access to high-quality therapies, reinforcing its role as a global leader in biopharmaceuticals.
Leading Innovative Products
Among its leading products is serplulimab, an anti-PD-1 monoclonal antibody that has achieved remarkable sales figures of RMB597.7 million. This innovative treatment has received approvals in multiple countries for various forms of lung cancer and continues to gain traction in international markets. Similarly, Henlius' breast cancer treatment, HANQUYOU (trastuzumab), has made significant strides, recording RMB1.4442 billion in global sales and achieving approvals in more than 50 countries.
Strategic Collaborations and Partnerships
Henlius has made strategic collaborations with industry leaders, including Abbott and Dr. Reddy's, securing exclusive licenses for the development and commercialization of biosimilars. These agreements ensure that Henlius can expand its product offerings within emerging markets while strengthening its commercial capabilities.
Advancing Core Products
Henlius continues to innovate across its portfolio, with promising developments in multiple disease areas. The company is advancing clinical trials for various therapies, including anti-PD-1 antibodies and ADC candidates. The success of these advances highlights Henlius' commitment to addressing unmet medical needs and enhancing clinical outcomes across different therapeutic areas.
Looking Ahead: Future Prospects for Henlius
As Henlius navigates through 2025, the company is well-positioned for sustained growth. It remains dedicated to its patient-centric approach and aims to bring affordable innovative treatments to patients worldwide. With continual investments in R&D and a strategic global expansion plan, Henlius is poised to make a lasting impact in the biopharmaceutical landscape.
Frequently Asked Questions
1. What was Henlius' revenue growth in the first half of 2025?
Henlius reported a revenue increase of 2.7% YoY, reaching approximately RMB2.8195 billion.
2. How much did Henlius spend on R&D in this period?
The company invested RMB995.4 million in research and development, a 21.3% increase from the previous year.
3. What products have contributed to Henlius' overseas profit growth?
Henlius' overseas products, including serplulimab and HANQUYOU, have significantly contributed to growth, with serplulimab seeing sales of RMB597.7 million.
4. In how many countries has Henlius launched its products?
Henlius has launched products in about 60 markets worldwide, benefiting over 850,000 patients.
5. What is the company's focus for the future?
Henlius focuses on driving global expansion and continuing innovation, ensuring access to high-quality, affordable treatments for patients globally.
